Renalytix AI plc is a kidney disease diagnostics company. Its lead product, KidneyIntelX is a blood test to predict risk of progression to end-stage renal disease. The company was founded in 2016 and is headquartered in London, the United Kingdom.
The Renalytix share price is down today after the company announced that it will be selling new shares to raise money for working capital. This move dilutes the value of existing shareholders’ holdings, and it’s never a good sign when a company has to resort to this kind of financing. Renalytix also said that it will be delaying the launch of its kidney disease diagnostic test, which was supposed to be its big commercial debut.
All in all, it’s been a tough few months for Renalytix and its shareholders.
The question now is whether or not Renalytix can turn things around. The company does have some promising technology, but it seems like every time there’s a bit of good news, there’s more bad news to follow.
It’ll be interesting to see how this plays out in the coming months, but for now, the outlook isn’t great.
Renalytix Share Price Nasdaq
Renalytix AI plc is a kidney disease diagnostics company. It focuses on developing and commercializing artificial intelligence-enabled blood tests to predict the onset of kidney disease, progression of renal function decline, and risk of adverse clinical outcomes such as cardiovascular disease and end stage renal disease. The company’s lead product candidate is KidneyIntelX, which is in pivotal Phase III clinical trial for chronic kidney disease (CKD) stratification in type 2 diabetes mellitus patients.
Credit: aithority.com
What is the Renalytix Share Price
Renalytix is a publicly traded company with shares listed on the Nasdaq stock exchange. As of February 2021, the Renalytix share price was $9.58 per share.
Renalytix is a kidney disease diagnostics company that develops and commercializes Artificial Intelligence (AI)-enabled blood tests for early risk detection and progression of kidney disease.
The company’s lead product, KidneyIntelX™, is being used by leading nephrology practices in the United States to help stratify patients at risk of rapid renal decline and those appropriate for proactive therapeutic intervention.
How Has the Renalytix Share Price Performed Over Time
Renalytix AI plc (LSE: RENX) is a kidney disease diagnostics company. The Company uses artificial intelligence to develop and commercialize blood tests for the early identification of kidney disease. It offers KidneyIntelX, a renal function test that analyzes biomarkers in a drop of blood to identify earlier stage kidney disease and risk factors for progression.
RenalytixAI plc is based in London, United Kingdom.
The Renalytix share price has performed well over time, rising steadily since its inception in 2015. The company’s strong financial performance and promising outlook have helped to drive the share price higher, and it has outperformed the wider stock market by a wide margin over the past five years.
Looking ahead, Renalytix appears well-positioned to continue its strong performance, with its cutting-edge technology set to revolutionize the way kidney disease is diagnosed and managed. As such, we believe the shares could continue to deliver strong returns for investors over the long term.
What Factors Have Influenced the Renalytix Share Price in the Past
Renalytix AI plc is a kidney disease diagnostics company. The Company uses artificial intelligence (AI) in vitro diagnostic (IVD) tools and machine learning algorithms to develop kidney disease tests. RenalytixAI’s integrated product suite is designed to provide actionable patient insights earlier in the course of kidney disease, enable proactive clinical management, and improve health economic outcomes.
The Company’s lead product, KidneyIntelX, is a blood test for risk prediction of progression to end-stage renal disease (ESRD).
Where Can I Find Information on Analyst Ratings for Renalytix Shares
If you’re looking for information on analyst ratings for Renalytix shares, the best place to start is with the company’s own website. On the investor relations page, you’ll find links to research reports from a number of major firms. These reports will give you an idea of where analysts believe the stock is headed in the future.
What is the Consensus among Analysts Regarding the Outlook for Renalytix Shares
The consensus among analysts is that the outlook for Renalytix shares is positive. The company has a strong product pipeline and is well-positioned to capitalize on the growing demand for kidney disease diagnostics and therapeutics. In addition, Renalytix has a solid financial position, with no debt and a cash balance of $85 million as of June 30, 2020.
Renalytix Stock $RNLX: Is growth finally here?
Conclusion
The Renalytix share price has been volatile in recent months, but the company’s technology is promising and could be a game-changer in the kidney disease space. The company’s AI-based software analyzes a patient’s blood test results to predict which patients are at risk of progressing to end-stage renal disease (ESRD). This is important because ESRD is expensive to treat and often leads to death.
Renalytix’s technology has the potential to save lives and reduce healthcare costs.
